Advancing Innovative Next-Generation Heterologous Vaccines Against Tuberculosis
This project is an NIH/NIAID R61 award to develop novel novel vaccine approaches against TB, including innovative vaccine adjuvants for subunit protein antigens, RNA vaccine antigens, and heterologous combinations of RNA and adjuvanted protein vaccine approaches in preclinical immunogenicity and efficacy models.
Faculty Involved